Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 10/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.64 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945162 | 1.00 | HDAC3 (0.64) | HDAC3HDAC1HDAC8HDAC6HDAC2 | |
| SCHEMBL2136860 | 0.91 | HDAC1 (0.64) | HDAC3HDAC1HDAC8HDAC6HDAC2 | |
| SCHEMBL2136864 | 0.91 | HDAC1 (0.64) | HDAC3HDAC1HDAC8HDAC6HDAC2 | |
| SCHEMBL2511497 | 0.89 | HDAC3 (0.78) | HDAC3HDAC1HDAC8HDAC6HDAC2 | |
| SCHEMBL12748793 | 0.88 | HDAC3 (0.67) | HDAC3HDAC1HDAC8HDAC6HDAC2 | |
| SCHEMBL2134760 | 0.85 | HDAC3 (0.55) | HDAC3HDAC1HDAC8HDAC6HDAC2 | |
| SCHEMBL30018535 | 0.85 | HDAC3 (0.55) | HDAC3HDAC1HDAC8HDAC6HDAC2 | |
| SCHEMBL3225137 | 0.85 | BACE1 (0.73) | HDAC3HDAC1HDAC8HDAC6HDAC2 | |
| SCHEMBL3225127 | 0.85 | BACE1 (0.73) | HDAC3HDAC1HDAC8HDAC6HDAC2 | |
| SCHEMBL18248236 | 0.83 | HDAC3 (0.52) | HDAC3HDAC1HDAC8HDAC6HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230120185-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-01 | — | — | US | disclosed |
| US-20210253532-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| US-10899716-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-01-26 | — | — | US | disclosed |
| EP-3298002-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-20200165205-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| EP-3632899-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RaQualia Pharma Inc. (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| EP-2435407-B1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2019-12-25 | — | — | EP | disclosed |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| EP-3298002-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016185423-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-11-24 | — | — | WO | disclosed |
| WO-2010137351-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590085-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | HDAC3 301/4885HDAC1 220/4885HDAC8 381/4885 |
| US-20210253532-A1 | Heterocyclic Amides as Kinase Inhibitors | MAP3K19, MAP3K20, MAP3K1 | HDAC3 298/4885HDAC1 219/4885HDAC8 371/4885 |
| US-20230120185-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | HDAC3 298/4885HDAC1 219/4885HDAC8 371/4885 |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | HDAC3 298/4885HDAC1 219/4885HDAC8 371/4885 |
| US-10899716-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | HDAC3 298/4885HDAC1 219/4885HDAC8 371/4885 |
| US-20200165205-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | HDAC3 298/4885HDAC1 219/4885HDAC8 371/4885 |
| US-20180134665-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | HDAC3 301/4885HDAC1 220/4885HDAC8 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.